866 related articles for article (PubMed ID: 35428347)
1. Emerging therapies for glioblastoma: current state and future directions.
Rong L; Li N; Zhang Z
J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
3. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
5. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
6. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
7. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H
Cells; 2024 Apr; 13(9):. PubMed ID: 38727262
[TBL] [Abstract][Full Text] [Related]
8. Advances in Glioblastoma Therapy: An Update on Current Approaches.
Angom RS; Nakka NMR; Bhattacharya S
Brain Sci; 2023 Oct; 13(11):. PubMed ID: 38002496
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of glioblastoma: Recent advances and future prospects.
Yuan B; Wang G; Tang X; Tong A; Zhou L
Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
[TBL] [Abstract][Full Text] [Related]
10. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
11. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
[TBL] [Abstract][Full Text] [Related]
12. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
[No Abstract] [Full Text] [Related]
13. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
[TBL] [Abstract][Full Text] [Related]
14. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
Prinzing BL; Gottschalk SM; Krenciute G
Expert Rev Anticancer Ther; 2018 May; 18(5):451-461. PubMed ID: 29533108
[TBL] [Abstract][Full Text] [Related]
15. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; Internò V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
Gedeon PC; Champion CD; Rhodin KE; Woroniecka K; Kemeny HR; Bramall AN; Bernstock JD; Choi BD; Sampson JH
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1147-1158. PubMed ID: 32862726
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for glioblastoma: the promise of combination strategies.
Bausart M; Préat V; Malfanti A
J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
[TBL] [Abstract][Full Text] [Related]
18. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
20. Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma.
Mooney J; Bernstock JD; Ilyas A; Ibrahim A; Yamashita D; Markert JM; Nakano I
World Neurosurg; 2019 Sep; 129():90-100. PubMed ID: 31152883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]